Page 30 - 2017食品藥物管理署年報(英文版)
P. 30

2017 Taiwan Food and Drug Administration Annual Report











                      Date             Title                       Key amendments
                                                    Starting from January 1, 2017, any cosmetics containing
                               Establish “Cosmetics must
                   June 30                          Antihistamine must not be sold, supplied, intended for sales
                               not contain Antihistamine”
                                                    or supplied for presentation.
                                                    Any cosmetics indicated or suggested for children
                                                    use should reduce the contents of fragrance, coloring
                               Establish “Guidelines   and preservatives, pay attention to the packaging and
                   October 14  of Cosmetics for Safe   prevent the product from being consumed by children. It
                               Children Use”        is recommended to label precautions. At the same time,
                                                    reiterate current regulations (health safety and labeling) in
                                                    the announcement.
                               Establish “Technical
                               Guidelines for Cosmetics   To complete the industrial development of domestic cosmetic
                               UVA Sunscreen        industries and reinforce cosmetics management and secure
                               Performance Tests    the safety of the subjects, TFDA established two Technical
                   November 8  (Human Subject Test)”   Guidelines for Cosmetics SPF Tests (human subject test) as
                               and “Technical Guidelines   the reference foundations for domestic cosmetic industries to
                               for Cosmetics Sunscreen   implement UVA as well as SPF efficacy tests of cosmetics.
                               Performance Tests
                               (Human Subject Test)”
                               Partial revision of the   Add “Except one of the special conditions which have
                               “Statute for Control of   been approved by central competent authorities, the safety
                   November 9  Cosmetic Hygiene” (Ban   assessments/tests of cosmetic finished products as well as
                               on Animal Testing for   ingredients on animal models are not allowed in Taiwan.
                               Cosmetics)
                               Dermal implants within
                               the identification scope of   After re-evaluate and secondary review of the safety and
                               “I.0007 Hyaluronic acid   performance of the products, it is believed that the type of
                   December 2                       product shall be included completely for safety surveillance.
                               implants” shall be included
                               completely for safety   It is hereby announcing the scope and regulations of product
                               surveillance         safety surveillance
                                                    The “Lists of Recognized Medical Device Product
                               “Lists of Recognized
                   December 13 Medical Device Product   Guidances” includes 20 medical devices, which offers
                               Guidances”           medical device industries as references for preparing
                                                    technical or pre-clinical test documents.



                  2. The implementation of registration, review, management and

                      counseling mechanisms for medicinal products and cosmetics
                  (1) Medicinal product registration management
                     Medicinal product registration can be divided into active pharmaceutical ingredients
                  (API) and its preparations, the latter of which can be further divided into new drugs,
                  biologics, generic drugs, and orphan drugs. Where local clinical trials or bioavailability







            28
   25   26   27   28   29   30   31   32   33   34   35